Dynavax ragweed data fuels big share jump

Shares of Dynavax took off this morning after the developer announced new data demonstrating the effectiveness of its experimental therapy for ragweed allergies. Ragweed allergy sufferers were given the therapy--AIC--for six weeks and typically experienced a reduction in symptoms for 12 months. Dynavax shares jumped 26 percent. "The demonstrated therapeutic properties and safety pave the way for a therapeutic intervention that is qualitatively superior to standard immunotherapy," said Dr. Peter Creticos, lead researcher in the trial and a physician at Johns Hopkins.

- read the report from TheStreet

Suggested Articles

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.